Brain energy and glutamate in schizophrenia
Part of Mental health clinical trials.
This study uses brain scans (MRI and PET) to look at energy use and a brain chemical called glutamate in people with schizophrenia. It compares healthy volunteers to those with well-controlled schizophrenia and those with hard-to-treat schizophrenia to understand the biology better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can be a healthy volunteer with no psychiatric history.
- Or you have schizophrenia that is well-controlled (in remission) and you take an antipsychotic like olanzapine, risperidone, quetiapine, amisulpride, aripiprazole, or paliperidone.
- Or you have treatment-resistant schizophrenia, you take clozapine or another listed antipsychotic, and your symptoms are moderate to severe.
- No diabetes or diabetic medication, no metal implants or electronic devices in your body, and no severe claustrophobia.
- Must be able to give informed consent and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
This study uses brain scans to look at how a specific brain area works in schizophrenia. If you qualify, it may help researchers better understand the brain changes linked to symptoms.
This study looks at how the nervous system and energy pathways in your body work in people with schizophrenia. It aims to find differences that could help improve future treatments.
This early (Phase 1) study uses a special brain scan to look at synapses—the contact points between brain cells—in people with schizophrenia-related conditions. It helps researchers understand brain activity and connection patterns, which may guide future tests or treatments.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
This study tests a brain stimulation treatment (neuromodulation) to improve brain connectivity in people with schizophrenia. It aims to see if this approach can help with symptoms and cognitive function.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.